The due diligence process helps investors assess level of risk of their investment into your startup. However, investors have different levels of risk tolerance, experience, and areas of focus. So how is a founding team to tailor their diligence package to appeal to a broad set of investors? Join us as we explore due diligence requirements and preferences of a variety of investors so that teams can develop comprehensive strategies with wide relevance and appeal.
This is the first of a two-part series. Our next panel in the series will explore strategies to prepare for diligence performed by professional investors, such as VCs and Family Funds.
This event will be held virtually and there will be a short networking session following the panel, giving attendees a chance to speak with other members of the life sciences community.
Speaker
Ana-Maria Visoiu, MPH
Managing Director, Golden Seeds
Manager Clinical Study Lead, Regeneron